Carregant...
The Rationale for BAFF Inhibition in Systemic Lupus Erythematosus
BAFF (B-cell–activating factor) is a critical survival factor for transitional and mature B cells and is a promising therapeutic target for systemic lupus erythematosus (SLE). In 2010–2011, two phase 3 clinical trials showed that the addition of the anti-BAFF antibody belimumab to standard-of-care t...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3389191/ https://ncbi.nlm.nih.gov/pubmed/22535567 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11926-012-0258-2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|